Skip to content
Homepage
Author:
ZENTALIS PHARMACEUTICALS
Posted Date:
November 3, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
ZENTALIS PHARMACEUTICALS
November 3, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZENTALIS PHARMACEUTICALS
November 2, 2026
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
ZENTALIS PHARMACEUTICALS
October 23, 2026
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
ZENTALIS PHARMACEUTICALS
October 18, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZENTALIS PHARMACEUTICALS
October 1, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
ZENTALIS PHARMACEUTICALS
September 2, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZENTALIS PHARMACEUTICALS
September 1, 2026
